Anixa Biosciences to receive new US patent for ovarian cancer vaccine

Anixa Biosciences (NASDAQ:ANIX) announced a new U.S. patent for its ovarian cancer vaccine technology, which targets AMHR2 and strengthens the company's intellectual property for this key asset developed with Cleveland Clinic and the NCI. This development coincides with significant clinical progress, including dosing the first patient in a higher-dose cohort for its CAR-T therapy for recurrent ovarian cancer, and completing enrollment for its breast cancer vaccine Phase 1 trial, which demonstrated promising preliminary results with over 70% of patients showing an immune response. H.C. Wainwright reiterated a Buy rating and $7.00 price target, underscoring growing analyst confidence in Anixa's advancing oncology pipeline and collaborative development strategy.

Analysis

Anixa Biosciences (NASDAQ:ANIX) is executing a multi-pronged strategy to de-risk its early-stage oncology pipeline, underscored by recent advancements in intellectual property and clinical trials. The forthcoming issuance of U.S. Patent 12,357,593 on July 15 significantly strengthens the company's competitive moat for its ovarian cancer vaccine by providing broad protection for methods targeting the AMHR2 receptor. This IP, exclusively licensed from Cleveland Clinic, is a cornerstone of a program developed with credible partners including the National Cancer Institute. Concurrently, Anixa is demonstrating clinical momentum across its portfolio. The company has advanced its CAR-T therapy for recurrent ovarian cancer to a fourth cohort in its Phase 1 trial, implementing a thirtyfold dosage increase, a critical step in evaluating safety and potential efficacy. Furthermore, its breast cancer vaccine program has completed enrollment for a Phase 1 trial, yielding promising preliminary data with over 70% of patients showing a protocol-defined immune response, which has been reinforced by a new patent allowance. This progress has prompted H.C. Wainwright to reiterate its Buy rating and a $7.00 price target, signaling analyst confidence that is reflected in the stock's nearly 40% appreciation over the past six months.

Key Decisions for Investors

• Investors may view the combination of strengthening intellectual property and positive early-stage clinical trial progress as validation of Anixa's development strategy, supporting the stock's recent momentum.
• Shareholders should monitor upcoming clinical milestones, especially data from the higher-dose CAR-T cohorts and more mature results from the breast cancer vaccine trial, as these will be key catalysts for the stock.
• Given the company's $101 million market capitalization and early clinical stage, positions in ANIX should be considered high-risk and are most suitable for investors with a long-term horizon and high tolerance for clinical trial and regulatory uncertainty.